HIGHLIGHTS
- What: The authors report a patient who presented with a generalized pustular eruption following adalimumab therapy for hidradenitis suppurativa (HS).
- Who: Christopher D. Markeson et al. from the Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, USA have published the research work: Review began 10/20/2024 Review ended 10/26/2024 Published 12/09/2024 © Copyright, in the Journal: (JOURNAL) of December/09,/2024
SUMMARY
Adalimumab is a human IgG monoclonal antibody targeting and neutralizing tumor necrosis factor (TNF) activity. Only 2-5% of patients receiving TNF inhibitors for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.